Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 4/20 | 0.70 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.57 |
| ▸ | PRMT3 | O60678 | 2/20 | 0.50 |
| ▸ | BAZ1A | Q9NRL2 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.49 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.49 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4969172 | 0.91 | EPHX1 (0.70) | EPHX1EPHX2PRMT3MEN1NPC1 | |
| SCHEMBL12196146 | 0.83 | EPHX1 (1.00) | EPHX1EPHX2PRMT3MEN1NPC1 | |
| SCHEMBL4964622 | 0.82 | RAB9A (0.60) | EPHX1EPHX2MEN1NPC1POLB | |
| SCHEMBL4964376 | 0.82 | RAB9A (0.60) | EPHX1EPHX2MEN1NPC1POLB | |
| SCHEMBL4963936 | 0.81 | MGLL (0.53) | EPHX1BAZ1AMEN1NPC1POLB | |
| SCHEMBL27389314 | 0.79 | MEN1 (0.76) | BAZ1AMEN1NPC1POLBMAPT | |
| SCHEMBL4963944 | 0.78 | P2RX7 (0.47) | EPHX1NPC1MAPTP2RX7 | |
| SCHEMBL4962880 | 0.78 | PRMT3 (0.72) | EPHX1EPHX2PRMT3 | |
| SCHEMBL15327135 | 0.77 | NPC1 (0.72) | MEN1NPC1POLBMAPTKMT2A | |
| SCHEMBL4962236 | 0.76 | FAAH (0.54) | BAZ1AMEN1NPC1POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101351495-A | fatty acid amide hydrolase inhibitors | ORGANON NV (NL) | 2009-01-21 | — | — | CN | disclosed |
| EP-1969051-A2 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | N.V. Organon (NL) | 2008-09-17 | — | — | EP | disclosed |
| WO-2008024139-A2 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | N.V. ORGANON (NL) | 2008-02-28 | — | — | WO | disclosed |
| WO-2007079180-A2 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | N.V. ORGANON (NL) | 2007-07-12 | — | — | WO | disclosed |
| US-20070155747-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | KADMUS PHARMACEUTICALS, INC. (US) | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155747-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, ABHD6 | EPHX1 84/4885EPHX2 72/4885PRMT3 3302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.